Published in Leukemia on September 01, 1999
Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol (2010) 1.30
Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int (2014) 0.98
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn (2008) 0.97
Expression of MTLC gene in gastric carcinoma. World J Gastroenterol (2003) 0.87
PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia. Cancer Biol Ther (2013) 0.84
The Human Proteome Organization Chromosome 6 Consortium: integrating chromosome-centric and biology/disease driven strategies. J Proteomics (2013) 0.80
miR deregulation in CLL. Adv Exp Med Biol (2013) 0.79
Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use? Haematologica (2010) 0.79
FISH Analysis for del6q21 and del17p13 in B-cell Chronic Lymphocytic Leukemia in Iranians. Iran Red Crescent Med J (2013) 0.77
Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation. Appl Clin Genet (2012) 0.75
Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran. Int J Hematol Oncol Stem Cell Res (2017) 0.75
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer (1997) 8.27
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12
Role of chromosome territories in the functional compartmentalization of the cell nucleus. Cold Spring Harb Symp Quant Biol (1993) 3.38
Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut (2010) 3.24
Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet (1993) 2.64
IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol (1999) 2.58
Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes. Hum Genet (1988) 2.52
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50
Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res (1998) 2.41
Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: identification of 11q23 translocation breakpoints with a yeast artificial chromosome. Proc Natl Acad Sci U S A (1990) 2.29
Active and inactive genes localize preferentially in the periphery of chromosome territories. J Cell Biol (1996) 2.25
Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc Natl Acad Sci U S A (2000) 2.22
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res (2000) 2.09
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08
Molecular characterization of a slowly gating human hyperpolarization-activated channel predominantly expressed in thalamus, heart, and testis. Proc Natl Acad Sci U S A (1999) 2.07
DNMT3A mutations in myeloproliferative neoplasms. Leukemia (2011) 1.95
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia (2009) 1.92
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86
Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood (1996) 1.85
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer (2008) 1.84
DNA microarray analysis identifies candidate regions and genes in unexplained mental retardation. Neurology (2007) 1.81
Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene (1998) 1.81
Chromosomal in situ suppression hybridization of human gonosomes and autosomes and its use in clinical cytogenetics. Hum Genet (1990) 1.81
Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A (1997) 1.76
Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res (1998) 1.75
Quantitative analysis of comparative genomic hybridization. Cytometry (1995) 1.72
Evidence for a nuclear compartment of transcription and splicing located at chromosome domain boundaries. Chromosome Res (1993) 1.72
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet (2001) 1.70
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood (1997) 1.69
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol (2001) 1.68
Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res (1998) 1.68
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product. Genomics (1990) 1.67
Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol (2002) 1.67
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia (2012) 1.64
Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res (1996) 1.63
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62
Laparoscopic restorative proctocolectomy. Br J Surg (2005) 1.60
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer (2005) 1.59
Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood (1999) 1.55
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res (2001) 1.51
High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood (1994) 1.50
Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis. Cell Death Differ (2007) 1.50
Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer (2001) 1.49
S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol (1999) 1.49
Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol (1999) 1.48
De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene (2010) 1.47
The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia (2006) 1.47
Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A (2000) 1.46
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood (1996) 1.46
Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol (2006) 1.45
Clustered arrangement of winged helix genes fkh-6 and MFH-1: possible implications for mesoderm development. Development (1996) 1.44
Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis (2003) 1.44
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia (2007) 1.43
Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer (1998) 1.42
Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals. Hum Gene Ther (1997) 1.41
Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia (2010) 1.41
APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol (1993) 1.39
Genomic imbalances are rare in hairy cell leukemia. Genes Chromosomes Cancer (1999) 1.39
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact. Leukemia (2000) 1.39